Ifosfamide is generic form of brand name Celofos
Celofos 1gm belongs to type of anti-cancer drug. This medication is classified as an "alkylating agent.
Celofos is a prescription drug which is used under the supervision of medical oncologist
1ml injection in a vial
Celofos 1gm is indicated for the treatment of following conditions;
• Relapsed testicular cancer and germ cell tumors
• Sarcomas (soft-tissue, osteogenic sarcoma, Ewing's sarcoma)
• Non-Hodgkin's lymphoma
• Hodgkin's disease
• Non-small cell and small cell lung cancer
• Bladder cancer
• Head and neck cancer
• Cervix cancer
The proper mechanism of Ifosfamide has not been described butoccur to be like other alkylating agents. Ifosfamide needed biotransformation in the Hepatic by mixed-function oxidases (cytochrome P450 system) before it becomes active. After metabolic activation, active metabolites of Ifosfamide alkylate or mix with many intracellular molecular structures, containing nucleic acids. The cytotoxic activities are mainly via the alkylation of DNA, done by affix the N-7 position of guanine to its reactive electrophilic groups. The inter and intra strand cross-links formation in the DNA causes in cell death.
Time to peak plasma of Celofos is 20-30 minutes and the bioavailability are 90-100%
volume of distribution is 33L
Celofos is extensively metabolized and has metabolites of 3-dechloroethylifosfamide, 2- dechloroethylifosfamide and carboxyifosfamide
Celofos is excreted at high dose of 5000mg/m2 in urine 70-86% and at low dose 1600-2400 about 12-16%.
Half- life for high dose of 3800-5000mg/m2is 15hr and 7hr for low dose of 1800-2400 mg/m2
DOSAGE AND ADMINISTRATION
For testicular cancer :
Usual adult dose is 1.2 g/m2, diluted to 50mg/mL IV over 30 minutes once a day with mesna administrated via IV, Oral, or continuous IV infusion given just before and 4 and 8 hours after each dose and aggressive hydration 2 to 4 L/day. Celofos is commonly administrated for 5days.
Repeated every 3 to 4 weeks
For cervical cancer :
The recommended dose in combination with other cancer drugs as a part of the BIP regimen is 5000mg/m2 over 24 hours on day 2 Cycle repeated every 21 days
The recommended dose in combination with other cancer drugs as a part of the BIC regimen is 2000mg/m2IV on day 1 through 3 Cycle repeated every 21 days
Paediatric dose for Malignant disease :
The recommended dose is 1200 to 1800mg/m2IV for 3 to 5 days every 21 to 28 days
Or administrated has 5000mg/m2 over 24 hours infusion or 3g/m2/ day for 2 days
Common side effects of Celofos 1gm :
• Low WBC count
• Low platelet count
• Loss of hair
• Fertility loss
• Vomiting and nausea
Less common side effects of Celofos 1gm :
• Central neurotoxicity
While treatment with Celofos 1gm may occur Bone marrow suppression
With Celofos 1gm causes Haemorrhagic cystitis reported
Stop treatment if it occurs Confusion and coma due to CNS toxicity have been associated with therapy.
Dose-related serious myelosuppression occurred